S'abonner

Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective - 05/08/20

Doi : 10.1016/j.jaci.2020.05.033 
Koa Hosoki, MD, PhD, Abhijit Chakraborty, PhD, Sanjiv Sur, MD
 Department of Medicine, Immunology Allergy and Rheumatology, Baylor College of Medicine, Houston, Tex 

Corresponding author: Sanjiv Sur, MD, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030.Baylor College of Medicine1 Baylor PlazaHoustonTX77030

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being “immune” to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration–approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them.

Le texte complet de cet article est disponible en PDF.

Key words : ACE2, asthma, allergic rhinitis, COVID-19, severe acute respiratory syndrome coronavirus 2, receptor-binding domain, TMPRSS2

Abbreviations used : ACE2, ARDS, CDC, CoV, COVID-19, FDA, IDO, JAK, MERS, MERS-CoV, MMWR, MX1, NIH, RBD, RSV, RV, SARS, SARS-CoV, SARS-CoV-2, S protein, TMPRSS2, WHO


Plan


 This research was supported by the National Heart, Lung, and Blood Institute (grant nos. 5R01HL145477-02 and 3R01HL145477-01S1) and the Department of Defense (grant no. PR171425 W81XWH-18-1-0743).
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2020  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 146 - N° 2

P. 285-299 - août 2020 Retour au numéro
Article précédent Article précédent
  • Taking the red out of eosinophilic inflammation in COPD
  • Robert K. Bush
| Article suivant Article suivant
  • Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
  • Peter Valent, Cem Akin, Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, Boguslaw Nedoszytko, Joseph H. Butterfield, Ivan Alvarez-Twose, Karl Sotlar, Juliana Schwaab, Mohamad Jawhar, Andreas Reiter, Mariana Castells, Wolfgang R. Sperr, Hanneke C. Kluin-Nelemans, Olivier Hermine, Jason Gotlib, Roberta Zanotti, Sigurd Broesby-Olsen, Hans-Peter Horny, Massimo Triggiani, Frank Siebenhaar, Alberto Orfao, Dean D. Metcalfe, Michel Arock, Karin Hartmann

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.